2.Modified endoscopic rhytidectomy in forehead and temporal area
Jintu ZHU ; Huasen QIU ; Shousong GAO ; Bo LIU ; Ning ZHANG ; Fei CHE ; Shaojun XU ; Xinghong SHANG
Chinese Journal of Medical Aesthetics and Cosmetology 2009;15(5):304-307
Objective To explore the aesthetic efficacy of modified endoscopic rhytidectomy by using the techniques to minimize tissue damage,to obviate injury to the vessels and nerves,and to control bleeding and to firm fixation.Methods Two discontinuous incisions were made in the temporal scalp during the procedure,obviating injury to the branches of the superficial temporal vessels.Endoscopic technique was used to facilitate elevating,hemostasis,slinging and fixation in the plane under superficial temporal fascia.Three transverse incisions were made after the hairline in the forhead scalp,the operation was carried out by using endoscopic equipment,and the elevated forhead flap was slinged and fixed upward to the lamina externa cranii.Results 58 cases were received endoscopic forehead and temporal rhytidectomy,only slight edema was observed after surgery,and no obvisous ecchymosis was found.All patients returned home 7 days after operation.Degree of satisfaction on long-term follow-up showed that 56 cases(96.55%)improved obviously one year postoperatively;35 cases followed up 2 years,33(94.29%)of them improved obviously.None case was suffered from facial nerve injury.Conclusion The purpose of endoscopic rhytidectomy is to avoid carrying out the operation out of sight,to minimize unexpected damage to vessels and nerves,and to facilitate dissection,hemostasis,suturing,slingling and fixation.By refining the technique,we can achieve minimal injury,shorten recovery period,and obtain more satisfactory results,so the indication for operation is extended.
3.Clinical outcomes and cost-utility after sirolimus-eluting versus bare metal stent implantation.
Fu-hai ZHAO ; Shu-zheng LÜ ; Hui LI ; Shang-qiu NING ; Fei YUAN ; Xian-tao SONG ; Ze-ning JIN ; Yuan ZHOU ; Xin CHEN ; Hong LIU ; Rui TIAN ; Kang MENG ; Hong LI ; Feng HAN
Chinese Medical Journal 2010;123(20):2797-2802
BACKGROUNDRandomized studies have shown beneficial effects of drug-eluting stent (DES) in reducing the risk of repeated revascularization. Other studies have shown higher proportion of death, myocardial infarction (MI) and increased cost concerning DES. However the long term safety and effectiveness of DES have been questioned recently.
METHODSTo compare long term clinical outcomes, health-related quality of life (HRQOL) and cost-utility after sirolimus-eluting stent (SES) and bare metal stent (BMS) implantation in angina patients in China, 1241 patients undergoing percutaneous coronary revascularization (PCI) with either SES (n = 632) or BMS (n = 609) were enrolled continuously in this prospective, nonrandomized, multi-center registry study.
RESULTSTotally 1570 stents were implanted for 1334 lesions. Follow-up was completed in 1205 (97.1%) patients at 12 months. Rates of MI, all causes of death were similar between the two groups. Significant differences were found at rate of cardiovascular re-hospitalization (136 (22.4%) in BMS group vs. 68 (10.8%) in SES group, P = 0.001) and recurrent angina (149 (24.5%) vs. 71 (11.3%), P = 0.001). Dramatic difference was observed when compared the baseline and 9-month HRQOL scores intra-group (P < 0.001). However no significant difference was found inter-group either in baseline or follow-up HRQOL. Compared with SES, the total cost in BMS was significantly lower on discharge (62 546.0 vs. 78 245.0 Yuan, P = 0.001). And follow-up expenditure was remarkably higher in the BMS group than that in the SES group (13 412.0 vs. 8 812.0 Yuan, P = 0.0001).
CONCLUSIONSThere were no significant differences on death, in-stent thrombosis, MI irrespective of stent type. SES was superior to BMS on improvement of life quality. SES was with higher cost-utility compared to BMS.
Adult ; Aged ; Angioplasty, Balloon, Coronary ; economics ; mortality ; Coronary Angiography ; Drug-Eluting Stents ; economics ; Female ; Health Care Costs ; Humans ; Immunosuppressive Agents ; administration & dosage ; Male ; Metals ; Middle Aged ; Prospective Studies ; Quality of Life ; Sirolimus ; administration & dosage ; Stents ; economics ; Treatment Outcome
4.Establishment and validation of finite element model for pelvis artery injury under impacts
Shang-cheng WANG ; Dong-mei WANG ; Ning-hua ZHANG ; Rui LIU ; Jing WANG ; Qiu-gen WANG
Journal of Medical Biomechanics 2014;29(3):E206-E212
Objective To construct and validate a 3D finite element model of pelvis-femur-soft tissue complex including artery, and investigate the mechanical response of pelvis artery under side impact loads. Methods The 3D finite element model of the pelvis-femur-soft tissue complex was constructed from CT images of one female volunteer, including bone tissues, arteries, enveloping soft tissues, cartilage and ligaments of the pelvic joints (sacroiliac joint, hip joint and pubic symphysis). The whole model utilized linear elastic solid elements to simulate bone tissues. Nonlinear elastic connector elements were employed to represent ligaments. Soft tissues, including the cartilage, enveloping soft tissues and arteries, were modeled as solid elements with hyper-elastic material. Side impact was conducted on the complex with impact mass of 22.1 kg at the impact velocity of 3.13 and 5 m/s, respectively, and the output of the complex model was then recorded. Results Simulation results matched the results of pelvic side impact experiments reported in literature. When the complex model was impacted at the velocity of 3.31 and 5 m/s, respectively, the maximum equivalent stress of arteries was 98 and 216 kPa, and the maximum principle strain was 14.9% and 20%, respectively. The risk of artery injury was relatively low. Conclusions This established pelvis-femur-artery complex model was validated and thus reliable to be used for investigating the dynamical response and injury analysis on pelvis artery under impact loads, and provides some biomechanical foundation for predicting artery injuries.
5.The genus Liriope: Phytochemistry and pharmacology.
Zhan-Peng SHANG ; Fei WANG ; Jia-Yu ZHANG ; Zi-Jian WANG ; Jian-Qiu LU ; Huai-You WANG ; Ning LI
Chinese Journal of Natural Medicines (English Ed.) 2017;15(11):801-815
Liriope (Liliaceae) species have been used as folk medicines in Asian countries since ancient times. From Liriope plants (8 species), a total of 132 compounds (except polysaccharides) have been isolated and identified, including steroidal saponins, flavonoids, phenols, and eudesmane sesquiterpenoids. The crude extracts or monomeric compounds from this genus have been shown to exhibit anti-tumor, anti-diabetic, anti-inflammatory, and neuroprotective activities. The present review summarizes the results on phytochemical and biological studies on Liriope plants. The chemotaxonomy of this genus is also discussed.
Animals
;
Anti-Inflammatory Agents
;
pharmacology
;
Antineoplastic Agents, Phytogenic
;
pharmacology
;
Flavonoids
;
pharmacology
;
Humans
;
Hypoglycemic Agents
;
pharmacology
;
Liriope Plant
;
chemistry
;
Medicine, Traditional
;
Neuroprotective Agents
;
pharmacology
;
Phenols
;
pharmacology
;
Phytotherapy
;
Plant Extracts
;
pharmacology
;
Saponins
;
pharmacology
;
Sesquiterpenes
;
pharmacology
6.Preliminary results of multicenter studies on ABO-incompatible kidney transplantation
Hongtao JIANG ; Tao LI ; Kun REN ; Xiaohua YU ; Yi WANG ; Shanbin ZHANG ; Desheng LI ; Huiling GAN ; Houqin LIU ; Liang XU ; Zhigang LUO ; Peigen GUI ; Xiangfang TAN ; Bingyi SHI ; Ming CAI ; Xiang LI ; Junnan XU ; Liang XU ; Tao LIN ; Xianding WANG ; Hongtao LIU ; Lexi ZHANG ; Jianyong WU ; Wenhua LEI ; Jiang QIU ; Guodong CHEN ; Jun LI ; Gang HUANG ; Chenglin WU ; Changxi WANG ; Lizhong CHEN ; Zheng CHEN ; Jiali FANG ; Xiaoming ZHANG ; Tongyi MEN ; Xianduo LI ; Chunbo MO ; Zhen WANG ; Xiaofeng SHI ; Guanghui PEI ; Jinpeng TU ; Xiaopeng HU ; Xiaodong ZHANG ; Ning LI ; Shaohua SHI ; Hua CHEN ; Zhenxing WANG ; Weiguo SUI ; Ying LI ; Qiang YAN ; Huaizhou CHEN ; Liusheng LAI ; Jinfeng LI ; Wenjun SHANG ; Guiwen FENG ; Gang CHEN ; Fanjun ZENG ; Lan ZHU ; Jun FANG ; Ruiming RONG ; Xuanchuan WANG ; Guisheng QI ; Qiang WANG ; Puxun TIAN ; Yang LI ; Xiaohui TIAN ; Heli XIANG ; Xiaoming PAN ; Xiaoming DING ; Wujun XUE ; Jiqiu WEN ; Xiaosong XU
Chinese Journal of Organ Transplantation 2020;41(5):259-264
Objective:To summarize the patient profiles and therapeutic efficacies of ABO-incompatible living-related kidney transplantations at 19 domestic transplant centers and provide rationales for clinical application of ABOi-KT.Methods:Clinical cases of ABO-incompatible/compatible kidney transplantation (ABOi-KT/ABOc-KT) from December 2006 to December 2009 were collected. Then, statistical analyses were conducted from the aspects of tissue matching, perioperative managements, complications and survival rates of renal allograft or recipients.Results:Clinical data of 342 ABOi-KT and 779 ABOc-KT indicated that (1) no inter-group differences existed in age, body mass index (BMI), donor-recipient relationship or waiting time of pre-operative dialysis; (2) ABO blood type: blood type O recipients had the longest waiting list and transplantations from blood type A to blood type O accounted for the largest proportion; (3) HLA matching: no statistical significance existed in mismatch rate or positive rate of PRA I/II between two types of surgery; (4) CD20 should be properly used on the basis of different phrases; (5) hemorrhage was a common complication during an early postoperative period and microthrombosis appeared later; (6) no difference existed in postoperative incidence of complications or survival rate of renal allograft and recipients at 1/3/5/10 years between ABOi-KT and ABOc-KT. The acute rejection rate and serum creatinine levels of ABOi-KT recipients were comparable to those of ABOc-KT recipients within 1 year.Conclusions:ABOi-KT is both safe and effective so that it may be applied at all transplant centers as needed.